Pfizer's bowel disease drug succeeds in late-stage study
Send a link to a friend
[March 24, 2022]
(Reuters) -Pfizer Inc said on
Wednesday its experimental treatment for an inflammatory bowel disease,
acquired last year as part of its $6.7 billion deal for Arena
Pharmaceuticals, succeeded in a late-stage trial.
The study was testing the efficacy and safety of etrasimod in patients
with moderate to severe ulcerative colitis, a chronic inflammatory
disease of the colon that leads to ulcers causing abdominal pain, bloody
stools and incontinence.
Inflammatory bowel disease is a $20 billion market globally, making it a
lucrative target for drugmakers.
[to top of second column]
|
![](../images/032422PIX/health15.jpg)
Pfizer logo seen outside their building in Manhattan, New York
City, New York, U.S., March 2, 2021. REUTERS/Carlo Allegri/File
Photo
![](http://archives.lincolndailynews.com/2022/Mar/24/images/ads/current/Applegate_sda_SFARM_2022.png) Etrasimod met the main goal of
statistically significant improvement in remission at week 12
compared to placebo. Statistically significant improvements were
achieved in all key secondary goals in the trial as well, the
company said.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Maju Samuel)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |